You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
再鼎醫藥(09688.HK):第二季度產品收入淨額1.001億美元 同比增長45%

格隆匯8月7日丨再鼎醫藥(09688.HK)發佈公吿,2024年第二季度產品收入淨額為1.001億美元,2023年同期為6,890萬美元,同比增長45%,按固定匯率計算同比增長47%。這一增長主要是由於衞偉迦於2023年9月上市以及2024年1月納入中國國家醫保藥品目錄(NRDL)後的銷量增加,以及則樂和紐再樂的銷售增長。

再鼎醫藥創始人、董事長兼首席執行官杜瑩博士表示:“第二季度,我們實現了出色的商業化增長,保持了審慎的財務支出,並在管線組合的各方面取得了重大進展,這些都突出了我們實現戰略目標的能力。衞偉迦的成功體現了重症肌無力患者對安全有效治療的迫切需求。我們將繼續優化資源分配,並重點投資那些有望顯著改善人類健康的高價值項目。近期我們通過基於新一代平台的ROR1 ADC ZL-6301進一步拓展了我們的全球腫瘤管線。此外,包括艾加莫德、bemarituzumab、KarXT和我們三款臨牀階段全球管線在內的進展,將使我們向着實現五年戰略計劃目標的方向邁進。”

再鼎醫藥總裁兼首席運營官Josh Smiley表示:“由於衞偉迦成功的商業化進展,我們第二季度的產品收入淨額同比增長45%,按固定匯率計算同比增長了47%。2024年,我們在繼續專注推進衞偉迦用於gMG的同時,也將為近期即將上市的若干新產品和新適應證做好準備。我們將努力打造更為強大高效的組織,並通過我們的創新管線,實現顯著的營收增長,力爭在2025年底前實現盈利。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account